drugset / Trial / NCT05219461

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

NCT05219461

Phase 1 Completed 48 enrolled Daewoong Bio Inc.
RandomizedParallel-groupDouble-blindScreening

Summary

A randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of the Pharmacokinetics, safety, and tolerability of rhEGF eye drops in healthy male subjects

Timeline

Start
2019-03-29
Primary completion
2019-11-13
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject NEPIDERMIN Protein / enzyme biologic 10 ug/ml Topical
Subject NEPIDERMIN Protein / enzyme biologic 50 ug/ml Topical
Subject NEPIDERMIN Protein / enzyme biologic 100 ug/ml Topical

Indications